On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | -3.07% | -10.73% | -78.06% |
05-09 | AEON Biopharma, Inc. Provides Update on Development Pipeline | CI |
05-03 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
111,500 KRW | +1.64% | -0.80% | 940M | ||
1.58 USD | -3.07% | -10.73% | 63.22M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.06% | 63.22M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd